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HBV pol geneAbstract Background: Concurrent infections with hepatitis B virus (HBV) and hepatitis C virus
(HCV) are increasingly recognized in patients with chronic hepatitis. In Egypt, the last decade
showed a remarkable decline in HBV infection associated with remarkable rise in HCV infection.
The probable impact of occult HBV in patients with chronic HCV infection has been previously
investigated and the evidence suggests a possible correlation with lower response to anti-viral treat-
ment, higher grades of liver histological changes, and development of hepatocellular carcinoma.
The aim of this study was to analyze the possible inﬂuence of occult HBV infection on the clinical
outcomes in chronic HCV patients and to compare conventional and real-time PCR in detecting
HBV DNA among Hepatitis B surface antigen (HBsAg) negative chronic HCV.
Methods: Sera collected from 100 chronic HCV patients (negative for HBsAg and positive for anti-
HCV and HCV RNA) were tested for anti-HBc, anti-HBe and anti-HBs by ELISA, HCV-RNA
viral load was determined by real-time PCR (TaqMan probe technique) and HBV DNA was
detected with primers encoding the surface (S), core (C), polymerase (pol) and X genes. In addition,
determination of liver enzymes including aspartate and alanine aminotransferases (AST, ALT)
activities was performed.
Results: Fifty-eight percent of the study group were positive for anti-HBc. Meanwhile, only 18
cases (18%) were positive for the polymerase gene by nested PCR and were considered as occult
HBV. Among these 18 polymerase gene positive patients (occult HBV) anti-HBc was detected
among 9 (50%) of cases. Different gene proﬁles were noticed among the 18 polymerase gene pos-
itive patients.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).365264.
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Hepatitis B virus (HBV) and hepatitis C virus (HCV) infec-
tions account for a substantial proportion of cases of chronic
liver disease including chronic hepatitis, cirrhosis, and liver
cancer.1 It is estimated that there are 240 million HBV carriers
and 130–150 million HCV carriers worldwide.2,3 HBV and
HCV are transmitted parenterally and share common routes
of infection; as a result, infection with both viruses may occur.1
The diagnosis of HBV infection is usually based on the
detection of hepatitis B surface antigen (HBsAg), and the dis-
appearance of this antigen indicates the clearance of HBV.4
However, it has been shown that HBV DNA can be detected
in patients with chronic liver disease who are negative for
HBsAg but positive for antibodies to hepatitis B core antigen
(anti-HBc). This so-called occult HBV (OBI) infection has fre-
quently been identiﬁed in patients with chronic HCV
infection.5,6
More recently, occult HBV infection has been considered to
play a role in chronic hepatitis C virus infected patients,
including the severity of HCV, related liver disease, poor
response to anti-HCV treatment and development of hepato-
cellular carcinoma (HCC).7–9
Owing to their distinct clinical course and heterogeneity,
identiﬁcation of patients who are candidates for therapy and
selection of the optimal antiviral therapy is a challenge for
clinicians.
The aim of this work was to study the possible inﬂuence of
occult HBV infection on the clinical outcomes in the HBsAg
negative chronic HCV patients and to compare conventional
and real-time PCR in detecting HBV DNA among infected
patients.2. Patients and methods
A cross-sectional study was carried out, it included 100 consec-
utive patients (negative for HBsAg and positive for anti-HCV
and HCV RNA) attending the Hepatology outpatient clinic
and diagnosed by the Microbiology Department in Medical
Research Institute, Alexandria, Egypt.
The study was carried out after receiving the approval of
the Ethics Committee in the Medical Research Institute. All
relevant information was collected from patients (after taking
full consent) including personal data.
Serawere collected fromall cases andwere tested for antibod-
ies against hepatitis B core antigen (anti-HBc), antibodies
against hepatitis B e antigen (anti-HBe), antibodies against hep-
atitis B s antigen (anti-HBs) (Abbott Murex Diagnostic Divi-
sion, Dartford, Kent, U.K) and determination of liver
enzymes; aspartate aminotransferase (AST), alanine amino-
transferase (ALT), total serumbilirubin and serum albumin.10,11
2.1. Quantitative detection of HCV RNA by real-time PCR
RNA extraction: RNA was extracted from serum specimens
using a QIAamp viral RNA kit (Qiagen Inc., Valencia, Cali-
fornia, USA) following manufacturer’s instructions. Ten ll
of extracted RNA was ampliﬁed by using 6 ll of HCV RG
Master A and 9 ll of HCV RG Master B to bring the reactionto a ﬁnal volume of 25 ll, with the PCR MX3000 stratagene
(Applied Biosystems Inc., Foster city, California, USA) sys-
tem. Thermal Proﬁle of ampliﬁcation included the following:
50 C for 30 min (reverse transcriptase step) followed by Ampli
Taq activation step at 95 C for 10 min, followed by a three
step PCR protocol: 95 C for 30 s and followed by annealing
at 50 C for 1 min and extension at 72 C for 30 s, for 40 cycles
with end point ﬂuorescence detection.
2.2. Detection of HBV DNA
2.2.1. HBV DNA extraction
DNA was extracted from serum using QIAamp viral DNA
mini kit (QIAGEN, Valencia, CA, United States) following
manufacturer’s instructions.
2.2.2. Detection of HBV-DNA by nested PCR using speciﬁc
primers for pol gene11
Sequences of primer pairs used for PCR to detect HBV genome11Primer
nameNucleotide sequence 50 to 30 Seq
id
noOuter primersHBPr 134
senseGCTGCTATGCCTCATCTTC 134HBPr 135
antisenseCA(G/A)AGACAAAAGAAAATTGG 135Inner primersHBPr 75
senseCAAGGTATGTTGCCCGTTTGTCC 75HBPr 94
antisenseGG(T/C)A(A/T)AAAGGGACTCA(A/C)GATG 94Outer ampliﬁcation components included the following:
0.3 ll (30 pmol) of each of; outer primers, 12.5 ll universal
PCR master mix 2-fold (GeneOn GmbH), 10 ll of Qiagen
extracted DNA and H2O was added to bring the reaction to
a ﬁnal volume of 25 ll. The DNA was ampliﬁed using the
following proﬁle: Ampli Taq activation for 95 C for 10 min,
followed by 40 cycles of PCR ampliﬁcation; denaturation
at 95 C for 30 s, annealing at 45 C for 30 s and extension
at 72 C for 30 s followed by ﬁnal elongation at 72 C for
10 min.
Nested ampliﬁcation components included the following:
3 ll of outer ampliﬁed products to be re-ampliﬁed using
0.3 ll (30 pmol) of each of; inner primers, 12.5 ll universal
PCR master mix 2-fold (GeneOn GmbH), and H2O was added
to bring the reaction to a ﬁnal volume of 25 ll. The second
round ampliﬁcation proﬁle was similar to the ﬁrst round but
only 35 cycles were carried out.
After ampliﬁcation, Ethidium bromide stained, 2% agarose
gel was prepared in TAE (Tris–acetate–EDTA, PH 8) buffer
and used for detection of the 341 base pair positive band. Fif-
teen ll of PCR product was run on 2% agarose gel at 100 V
for 45 min. A 100 bp DNA marker was used to identify the
ampliﬁed bands.
Detection of occult hepatitis B virus 1172.2.3. Ampliﬁcation of S, C and X genes of HBV by SYBR green
real-time PCR (AB: Applied Biosystem) using speciﬁc
primers12
Nucleotide sequence 50 to 30 NucleotideTable 1 Co
abnormal liv
cases:
HCV viral
load 6 104
105 –P108
Pearson Chi
square
ALT: alanine
FEp: Fischer e
X2: Chi squar
* Results 6.0rrelation between HCV RNA vir
er functions among the 100 anti-
No (%)
N= 100
Abnormal
ALT
15 (15%) 1 (6.7%)
85 (85%) 45 (52.9%)
0.001*
aminotransferase, AST: aminotransfe
xact test.
e test.
5 are signiﬁcant.positionSurface geneS-sense AGAACATCGCATCAGGACTC 159–178S-antisense CATAGGTATCTTGCGAAAGC 642–623Core geneC sense CTGGGAGGAGTTGGGGGA 1730–1747C antisense GTAGAAGAATAAAGCCC 2503–2487X geneX sense CTAGCCGCTTGTTTTGCTCG 1282–1301X antisense TTATGCCTACAGCCTCCTAG 1666–1647The ampliﬁcation reaction was performed as follows:
For ampliﬁcation of each gene: 0.3 ll (30 pmol) of HB s or
c, or x gene sense and antisense primers, 12.5 ll syber green
universal PCR master mix 2-fold (AB applied biosystem, Uni-
ted States), 10 ll of Qiagen extracted DNA and H2o was
added to bring the reaction to a ﬁnal volume of 25 ll. After
AmpliTaq activation at 95 C for 10 min, the DNA was ampli-
ﬁed for 40 cycles of PCR ampliﬁcation. Each cycle entailed:
denaturation at 95 C for 15 s, annealing at 55 C for 30 s
and extension at 72 C for 1 min. This was followed by melting
curve analysis to determine the purity and speciﬁcity of the
ampliﬁcation product. The melting curve analysis proﬁle was
95 C for 1 min, 50 C for 30 s, and 95 C for 15 s.
3. Results
The 100 anti-HCV positive patients included in this study
included 64 (64%) males and 36 (36%) females, with a male
to female ratio of 1.7:1. Their age ranged from (20–60) years.
Forty-ﬁve percent of them were in the (31–40) age group.
3.1. HCV RNA viral load
The majority of the 100 anti-HCV patients (85%) had high vir-
emia (105–108) IU/mL, meanwhile, only (15%) had low level
viremia of less than 104 IU/ml. High HCV viral load (aboveal load, with
HCV positive
Abnormal
AST
4 (26.6%)
59 (69.4%)
0.002*
rase.105) was highly associated with abnormal liver functions
(Table 1).
3.2. Occult HBV OR pol gene
Out of the 100 HCV RNA positive HBsAg negative patients,
58% were positive for anti-HBc. Meanwhile, only 18 cases
(18%) were positive for the polymerase gene by nested PCR
and were considered as occult HBV. Among the 18 polymerase
gene positive patients (occult HBV, OBI) anti-HBc was
detected among 9 (50%) of cases (Fig. 1).
3.3. Co HCV/HBV infection
94.5% of patients with dual HCV/occult-HBV infection had
HCV RNA viral load of 105–106 IU/ml, compared to 80% of
patients with single HCV infection. No signiﬁcant association
was found between HCV viral load and pol gene positivity.
Interestingly 77% and 55% of the patients with dual HCV/
occult-HBV infection had abnormalAST andALT respectively,
compared to 57% and 38% among patients with single HCV
infection.
3.4. S, X and C genes
The 100 HCV positive patients were tested for the S, X and C
genes by using SYBR Green real time, followed by dissociation
curve analysis. Different gene proﬁles were noticed among the
18 polymerase gene positive patients with occult HBV infec-
tion. No signiﬁcant association was found between the differ-
ent gene proﬁles and abnormal AST and ALT levels (Table 2,
Figs. 2–4).
3.5. Correlation between anti-core positivity, liver function tests
and HCV viral load
The anti-core positivity was not signiﬁcantly associated with
the different liver functions. As, out of the 18 OBI patients,
no difference among anti-HBc positive and anti-HBc negative
patients was found as; 77.8% and 55.5% of either groups had
elevated AST and ALT respectively (Table 3).
No signiﬁcant association was noticed between anti-HBc
positivity and HCV viral load as; 100% of anti-core positive
compared to 89% of anti-core negative patients had HCV-
RNA level of >105 IU/mL). However, only 11% of anti-
core negative patients showed low HCV viremia (6104 IU/ml).Figure 1 Gel electrophoresis of nested PCR product. Lane (1):
DNA ladder – 100 bp. Lane (2): positive control. Lane (3, 4):
positive samples. Lane (5, 6, 7): negative samples.
Table 2 Distribution of S, X, C and pol genes proﬁle and liver enzymes among the 100 HCV positive patients.
Gene proﬁle No % AST ALT
Normal Abnormal Normal Abnormal
S+ C+ X+ pol 1 1 1 0 1 0
C+ X+ pol 4 4 2 2 2 2
S+ pol 2 2 2 0 1 1
C+ pol 5 5 0 5 1 4
X+ pol 1 1 0 1 1
pol gene alone 5 5 1 4 2 3
No gene detected 82 82 36 46 51 31
Total 100 100.0
FEp = 0.082 FEp = 0.488
FEp: Fischer exact test.
X2: Chi square test.
*Results 6.05 are signiﬁcant.
Figure 2 Dissociation curve of s gene.
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Worldwide, HBV is the primary cause of cirrhosis and HCC
and is one of the ten leading causes of death.13
Occult HBV infection has frequently been identiﬁed in
patients with chronic HCV infection.14,15 This occult infectionmay be associated with more severe liver damage and even the
development of hepatocellular carcinoma (HCC).16,17
This study included 100 HCV RNA positive patients; 64
(64%) were males, 36 (36%) females, with a male to female
ratio of 1.7:1. The age of the study group ranged from
(20–60) years, 45% of them were in the (31–40) age group.
The majority of anti-HCV patients (85%) had high viremia
(>105 IU/ml), meanwhile, only (15%) had low level viremia
Figure 3 Dissociation curve of c gene.
Detection of occult hepatitis B virus 119of (6105 IU/ml). Abnormal serum ALT and AST were found
to be statistically associated with high HCV viral load.
As viral DNA levels in occult hepatitis B are very low, the
identiﬁcation of occult hepatitis B is strongly dependent on
both the sensitivity and the speciﬁcity of the assay. Current
technologies used for DNA detection are as follows: nested-
PCR, real-time PCR, and transcription mediated ampliﬁcation
(TMA). Primers must be speciﬁc for different HBV genomic
regions and complementary to highly conserved (genotype
shared) nucleotide sequences.11,18
Based on several studies, conventional nested PCR using
speciﬁc primers targeting the pol gene was found to be a highly
sensitive technique for detection of OBI.19 Based on these data,
the 100 chronic HCV patients enrolled in the current study
were tested for anti-HBc and pol gene was ampliﬁed using
nested PCR.
In this speciﬁc high-risk group, several studies have been
conducted worldwide. The available data on the frequency of
occult HBV infection are widely divergent. OBI seems to be
highly prevalent in Asia.20 Although the prevalence of occult
hepatitis B in patients with chronic hepatitis varies, the highest
prevalence is among hepatitis C patients.21 There is general
agreement that patients infected with HCV should be consid-
ered as a category of individuals with high prevalence of occult
hepatitis B.22 The incidence of OBI in HCV patients varies
greatly, ranging from 0% to 52%.23
In the current study, out of the 100 CHC patients 18 cases
(18%) were positive for the pol gene by nested PCR (OBI).Similar results were reported in several studies.24–28 Also, our
results agree with that reported among Mediterranean coun-
tries since HBV-DNA was detectable in about one-third of
HBsAg negative HCV carriers in the Mediterranean basin.29,30
In 2011, Selim et al.,25 repotted that 23 (38.3%) of 60
chronic Egyptian hepatitis C patients had detectable HBV-
DNA, despite the absence of circulating HBsAg.
In Lebanon, an overall rate of 16.3% of occult HBV was
detected among chronic HCV patients.30 Georgiadou et al.,31
demonstrated that almost one quarter of HCV-
positive/HBsAg-negative Greek patients had detectable
HBV-DNA by PCR. Higher prevalence was reported in Far
East Asian countries by using PCR, as the prevalence of
OBI in Chinese patients with chronic HCV infection was
41.9%.32
The difference in the reported prevalence may be due to a
multitude of reasons. This difference is attributed mainly to
geographical variation regarding HBV endemicity in these
countries. Risk factors for hepatitis B infection and the
biomarkers of hepatitis B infection are different in the studied
populations, and also, different in terms of sensitivity and
detection limit of the assay used (standard/nested PCR, real-
time PCR, etc.). The number of HBV DNA domains examined
and the biological compartment explored (liver, plasma, or
both) play an important role.
There have been signiﬁcant advances in understanding the
molecular mechanisms underlying occult HBV infection in
the last decade; the stability and long-term persistence of viral
Figure 4 Dissociation curve of x gene.
Table 3 Distribution of liver function tests and anti-HBc among the 18 OBI patients.
Anti-core +ve Anti-core ve Total Fischer exact P value
Normal Abnormal Total Normal Abnormal Total
No % No % No % No % No % No %
Liver function Dist
AST 2 22.2 7 77.8 9 100.0 2 22.2 7 77.8 9 100.0 18 1
ALT 4 44.5 5 55.5 9 100.0 4 44.5 5 55.5 9 100.0 18 1
anti-HBe: antibodies against hepatitis Be antigen, ALT: alanine aminotransferase, AST: aminotransferase.
FEp: Fischer exact test.
X2: Chi square test.
*Results 6.05 are signiﬁcant.
120 O.A.E.K. Mahmoud et al.covalently closed circular DNA (cccDNA) molecules together
with the long half-life of hepatocytes imply that HBV infec-
tion, once it has occurred, may possibly continue for life. There
is persistence of low HBV-DNA levels and lack of detectable
HBsAg in patients with OBI remains largely unknown
although the condition is probably multifactorial. Both host
and viral factors may be involved.29–34
Among the host factors, the host immune response may
play a role in keeping viral replication at low levels character-
istic of OBI or hindrance of HBsAg through circulating
immune complex. Likewise, hepatic cytokines such as TNF-a
and IFN-b may inhibit viral replication and activation. Mean-while, reduced HBV viremia may result from extra-hepatic
HBV replication such as that takes place in polymorph-
nuclear cells (PBMCs). Patients with long-standing abnormal
results of liver function tests with unknown etiology may have
HBV-DNA in their PBMCs in the absence of HBV markers,
serum HBV-DNA.35
Regarding viral factors any mutation that changes the anti-
genicity of the HBsAg or that decreases the synthesis of this
antigen or blockage of free HBsAg secretion may be the cause
of the lack of detection of HBsAg in patients with OBI (HBV
variants).36 Additional mechanisms for OBI have been thor-
oughly investigated, emphasizing that integration of viral
Detection of occult hepatitis B virus 121sequence may alter HBsAg expression and decrease HBV repli-
cation. Mutations in the regulatory regions of the HBV gen-
ome or the polymerase domain or in the s gene cause
HBsAg to be undetectable by commercial assays.11,37
Early studies reported a higher prevalence of HBV-DNA
detection in anti-HBc-positive than in anti-HBc negative
patients.38,39 In this study the pol gene was equally detected
among both anti-HBc positive (50%) and anti-HBc negative
patients (50%).
Ramia S et al.,30 detected HBV DNA in 41% of anti-core
positive patients compared to 7.1% of anti-core negative
chronic HCV patients
Detection of HBV DNA from serum or liver samples is
considered the gold standard for the diagnosis of occult
HBV infection. Experts have recently recommended the use
of highly sensitive nested PCR or real-time PCR assays that
can detect fewer than 10 copies of HBV DNA for the diagnosis
of occult HBV infection. In addition, testing for multiple tar-
gets on the HBV genome increases HBV DNA detection
rates.37
In the present study, we tested two technical procedures
regarding their speciﬁcity and sensitivity: real-time PCR
namely SYBR Green (amplifying S, C and X genes) and nested
PCR with primers targeting the region encoding the pol gene.
Using three sets of primers, speciﬁc for HBV surface, core
and X genes, different gene proﬁles were noticed among the
18 chronic HCV patients with occult HBV infection as follows:
the 4 genes (pol, S, C, X) combination was only detected
among one patient (5.5%), (pol, C, X) gene combination was
detected in 4 patients (22.3%). However pol and S genes, pol
and C genes and pol, X genes were detected solely in 2 patients
(11%), 5 patients (27.8%), and one patient (5.5%) respectively.
On the other hand, 5 cases (27.8%) positive for pol gene, were
negative for the other 3 genes.
Different results were reported by Kader et al.40 among
Sudanese blood donors as there were two main proﬁles,
namely the presence of the s, c, x genes together in 33.3% of
the blood donors or the presence of x gene in addition to the
core gene in 38% of their study group.
Our results disagree with those of Allice et al.41 who
reported that HBV Cobas TaqMan real-time PCR seems com-
pletely appropriate for exploration of occult hepatitis.42
On the other hand, several studies reported that the use of
COBAS TaqMan HBV PCR assay to screen OBI has not pro-
vided information similar to that reported using nested
PCR.43–46 Fujiwara et al.,47 used a real-time PCR for quanti-
tation of HBV-DNA. They reported that the detection rate
was slightly lower than that in other studies using different
techniques. The speciﬁcity of the results was usually enhanced
by using nested PCR with two rounds of ampliﬁcation and pri-
mers amplifying different targets.
The gold standard test for detection of OBI is the ampliﬁ-
cation of HBV-DNA. At present, the optimal standard for
diagnosis is the analysis of HBV-DNA extracts performed by
real-time, nested PCR techniques. False results of these assays
could be avoided by choosing PCR primers that span at least
three genomic regions of the HBV genome such as the s, x and
c genes, and validation should require detection from at least
two regions of the genome. This suggestion is not usually ful-
ﬁlled, and only one segment of a region is ampliﬁed.12,34,48
Patients with both HBV and HCV infections may show a
large spectrum of virological proﬁles.49 HCV infection cansuppress HBV replication, as demonstrated by studies showing
that patients with chronic hepatitis B who are coinfected with
HCV have lower HBV-DNA levels, decreased activity of
HBV-DNA polymerase, and decreased expression of HBsAg
and HBcAg in the liver.50,51 Moreover, patients with chronic
HBV infection who become superinfected with HCV can
undergo seroconversion of HBsAg. This effect may be medi-
ated by the host immune response (via the induction of cytoki-
nes such as IFNs) or by a direct effect of HCV proteins. Direct
interference mediated by HCV proteins can occur in vivo only
if both HBV and HCV coexist in the same hepatocyte.52
Several studies53,54,15 emphasized on the clinical impact of
silent HBV in patients suffering from chronic liver disease as a
result of HCV and reported that higher levels of the liver disease
severity were seen. It has been suggested that HBV replication
accounts for many of the liver enzyme ﬂares in patients co-
infectedwithHCVandoccultHBV, and is associatedwith ﬁbro-
sis/cirrhosis.55,56 However, in the current study, no signiﬁcant
association was found between OBI and the liver function tests
either in the anti-core positive or anti-core negative patients.
5. Conclusion
From this study we can conclude that occult hepatitis B is
observed in a considerable number of hepatitis C patients in
Egypt. Routine serological proﬁles are not always reliable in
determining status of HBV infection. Prospective studies are
also required to establish the relative risk of HCC among indi-
viduals with HBsAg negative chronic liver disease and HCV
coinfection.
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